Health Affairs, 28, no. 6 (2009): 1774-1777 doi: 10.1377/hlthaff.28.6.1774 © 2009 by Project HOPE	New Online   Senate Health Reform Bill   Rewarding Providers   Public Option Policy Brief   Health Reform & Abortion   Delivery System Reform

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Google Scholar Articles by Geraghty, J. A. PubMed PubMed Citation Articles by Geraghty, J. A. Related Collections Access To Care Health Promotion/Disease Prevention International Issues Business Of Health Public Health Health Spending

Perspective

PERSPECTIVE

Expanding The Biopharmaceutical Industry’s Involvement In Fighting Neglected Diseases

The increasingly recognized need for new products for so-called neglected diseases, which afflict large numbers of people but have received relatively little industry investment, presents a clear example of a "strategic" corporate responsibility. Addressing neglected diseases can be important to "health diplomacy" and other national interests as well. Because industrial capabilities are essential to the development of new drugs and vaccines for these diseases, specific policy initiatives to attract more companies to do such work should also be further developed.

                      What's this?